Journal of Clinical Oncology, Vol 3, 818-826, Copyright © 1985 by American Society of Clinical Oncology

ARTICLES

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

KK Jain, ES Casper, NL Geller, TB Hakes, RJ Kaufman, V Currie, W Schwartz, C Cassidy, GR Petroni and CW Young

Fifty-four patients with advanced breast cancer who had failed prior non-anthracycline combination chemotherapy were randomized to treatment with either epirubicin 85 mg/m2 or doxorubicin 60 mg/m2 intravenously every three weeks. Of 52 evaluable patients, 25% (six of 24) treated with epirubicin, and 25% (seven of 28) treated with doxorubicin experienced major therapeutic responses. The median duration of response to epirubicin was 11.9 months compared to 7.1 months with doxorubicin. Cardiotoxicity was monitored by serial multigated radionuclide cineangiocardiography performed at rest and after exercise. Laboratory evidence of cardiotoxicity was defined as a decrease in resting left ventricular ejection fraction of greater than 10% from the baseline value, or a decrease of 5% or greater with exercise compared with the resting study performed on the same day. Fifteen patients treated with epirubicin and 18 patients treated with doxorubicin had at least two determinations of left ventricular ejection fraction and were evaluable for laboratory cardiotoxicity. Using methods of survival analysis, the median doses to the development of laboratory cardiotoxicity were estimated to be 935 mg/m2 of epirubicin and 468 mg/m2 of doxorubicin. Four patients treated with epirubicin and five treated with doxorubicin developed symptomatic congestive heart failure. The median cumulative dose at which congestive heart failure occurred was 1,134 mg/m2 of epirubicin compared with 492 mg/m2 of doxorubicin. Fewer episodes of nausea and vomiting were observed in patients receiving epirubicin. Epirubicin is a new anthracycline with reduced cardiac toxicity, but preserved efficacy in the treatment of patients with advanced breast cancer.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Ryberg, D. Nielsen, G. Cortese, G. Nielsen, T. Skovsgaard, and P. K. Andersen New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients J Natl Cancer Inst, August 6, 2008; 100(15): 1058 - 1067. [Abstract] [Full Text] [PDF]

				B. L. Frei and S. A. Soefje A Review of the Cardiovascular Effects of Oncology Agents Journal of Pharmacy Practice, April 1, 2008; 21(2): 146 - 158. [Abstract] [PDF]

				M. N. Levine, K. I. Pritchard, V. H.C. Bramwell, L. E. Shepherd, D. Tu, and N. Paul Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5 J. Clin. Oncol., August 1, 2005; 23(22): 5166 - 5170. [Abstract] [Full Text] [PDF]

				G. J. Ventura Cardiotoxicity of Epirubicin Versus Doxorubicin: Cost and Clinical Results J. Clin. Oncol., April 20, 2005; 23(12): 2873 - 2873. [Full Text] [PDF]

				J. Bonneterre In Reply: J. Clin. Oncol., April 20, 2005; 23(12): 2873 - 2874. [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				M. E. R. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. G. Kieback, P. Tomczak, S. P. Ackland, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil(R)) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Onc., March 1, 2004; 15(3): 440 - 449. [Abstract] [Full Text] [PDF]

				L. M. Schuchter, M. L. Hensley, N. J. Meropol, and E. P. Winer 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., June 15, 2002; 20(12): 2895 - 2903. [Full Text] [PDF]

				M.I. Gharib and A.K. Burnett Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis Eur J Heart Fail, June 1, 2002; 4(3): 235 - 242. [Abstract] [Full Text] [PDF]

				L. B. Michaud and K. L. Jones Recent Advances in the Systemic Management of Metastatic Breast Cancer Journal of Pharmacy Practice, February 1, 2002; 15(1): 52 - 61. [Abstract] [PDF]

				C.-J. Tai, W.-S. Wang, J.-H. Liu, C.-C. Yen, F. S. Fan, T.-J. Chiou, and P.-M. Chen Salvage Therapy with Single-agent Paclitaxel by Three-hour Infusion in Metastatic Breast Cancer: an Experience in Taipei Veterans General Hospital Jpn. J. Clin. Oncol., October 1, 2001; 31(10): 477 - 481. [Abstract] [Full Text] [PDF]

				S. P. Ackland, A. Anton, G. P. Breitbach, E. Colajori, J. M. Tursi, C. Delfino, A. Efremidis, A. Ezzat, A. Fittipaldo, K. Kolaric, et al. Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study J. Clin. Oncol., February 15, 2001; 19(4): 943 - 953. [Abstract] [Full Text] [PDF]

				R. Paridaens, L. Biganzoli, P. Bruning, J. G. M. Klijn, T. Gamucci, S. Houston, R. Coleman, J. Schachter, A. Van Vreckem, R. Sylvester, et al. Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over J. Clin. Oncol., February 14, 2000; 18(4): 724 - 724. [Abstract] [Full Text] [PDF]

				A. Gennari, B. Salvadori, S. Donati, C. Bengala, C. Orlandini, R. Danesi, M. Del Tacca, P. Bruzzi, and P. F. Conte Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors J. Clin. Oncol., November 1, 1999; 17(11): 3596 - 3602. [Abstract] [Full Text] [PDF]